Research programme: glycan and glycolipid synthesis inhibitors - BioMarin Pharmaceutical/Pfizer

Drug Profile

Research programme: glycan and glycolipid synthesis inhibitors - BioMarin Pharmaceutical/Pfizer

Latest Information Update: 05 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zacharon Pharmaceuticals
  • Developer BioMarin Pharmaceutical; Zacharon Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Ganglioside inhibitors; Glycosaminoglycan inhibitors; Polysaccharide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gangliosidoses; Mucopolysaccharidosis I; Mucopolysaccharidosis II; Mucopolysaccharidosis III
  • No development reported Brain cancer

Most Recent Events

  • 26 Jul 2013 Preclinical development for mucopolysaccharidoses and gangliosidoses is ongoing in USA
  • 07 Jan 2013 Zacharon Pharmaceuticals has been acquired by BioMarin Pharmaceutical
  • 07 Apr 2011 Zacharon Pharmaceuticals and Pfizer enter into a research and development collaboration for the development of lysosomal storage disease therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top